A survey of South Carolina pharmacists' readiness to prescribe human immunodeficiency virus pre‐exposure prophylaxis
Open Access
- 13 March 2023
- journal article
- research article
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 6 (4) , 329-338
Abstract
Introduction: Human immunodeficiency virus (HIV) pre‐exposure prophylaxis (PrEP) is largely underutilized in the Southern United States. Given their community presence, pharmacists are well positioned to provide PrEP within rural, Southern regions. However, pharmacists' readiness to prescribe PrEP in these communities remains unknown.Objective: To determine the perceived feasibility and acceptability of prescribing PrEP by pharmacists in South Carolina (SC).Methods: We distributed a 43‐question online descriptive survey through the University of South Carolina Kennedy Pharmacy Innovation Center's listserv of licensed SC pharmacists. We assessed pharmacists' comfort, knowledge, and readiness to provide PrEP.Results: A total of 150 pharmacists responded to the survey. The majority were White (73%, n = 110), female (62%, n = 93), and non‐Hispanic (83%, n = 125). Pharmacists practiced in retail (25%, n = 37), hospital (22%, n = 33), independent (17%, n = 25), community (13%, n = 19), specialty (6%, n = 9), and academic settings (3%, n = 4); 11% (n = 17) practiced in rural locales. Pharmacists viewed PrEP as both effective (97%, n = 122/125) and beneficial (74% n = 97/131) for their clients. Many pharmacists reported being ready (60% n = 79/130) and willing (86% n = 111/129) to prescribe PrEP, although over half (62% n = 73/118) cited lack of PrEP knowledge as a barrier. Pharmacists described pharmacies as an appropriate location to prescribe PrEP (72% n = 97/134).Conclusions: Most SC pharmacists surveyed considered PrEP to be effective and beneficial for individuals who frequent their pharmacy and are willing to prescribe this therapy if statewide statutes allow. Many felt that pharmacies are an appropriate location to prescribe PrEP but lack a complete understanding of required protocols to manage these patients. Further investigation into facilitators and barriers of pharmacy‐driven PrEP is needed to enhance utilization within communities.Keywords
Funding Information
- Center for AIDS Research, Duke University (5P30 AI064518)
- National Institute of Allergy and Infectious Diseases (T32AI007392)
This publication has 33 references indexed in Scilit:
- Pharmacist prescribing: A scoping review about the views and experiences of patients and the publicResearch in Social and Administrative Pharmacy, 2017
- Understanding community pharmacist perceptions and knowledge about HIV preexposure prophylaxis (PrEP) therapy in a Mountain West stateJournal of the American Pharmacists Association, 2016
- The Continuum of Pharmacist Prescriptive AuthorityAnnals of Pharmacotherapy, 2016
- Response rate, response time, and economic costs of survey research: A randomized trial of practicing pharmacistsResearch in Social and Administrative Pharmacy, 2016
- Exploratory survey of Florida pharmacists’ experience, knowledge, and perception of HIV pre-exposure prophylaxisJournal of the American Pharmacists Association, 2014
- Expanding the Role of a Pharmacist as a Sexually Transmitted Infection Provider in the Setting of an Urban Free Health ClinicSexually Transmitted Diseases, 2013
- We Can Do More Than Just Sell the Test: Pharmacist Perspectives About Over-the-Counter Rapid HIV TestsAIDS and Behavior, 2013
- Antiretroviral Therapy Adherence, Medication Use, and Health Care Costs During 3 Years of a Community Pharmacy Medication Therapy Management Program for Medi-Cal Beneficiaries with HIV/AIDSJournal of Managed Care Pharmacy, 2011
- Exploring patient-pharmacist interaction differences between the drive-through and walk-in windowsJournal of the American Pharmacists Association, 2009
- Pharmacy- and Community-Based Screenings for Diabetes and Cardiovascular Conditions in High-Risk IndividualsJournal of the American Pharmacists Association, 2006